Previous close | 0.00 |
Open | 17.53 |
Bid | 15.68 x 47300 |
Ask | 18.04 x 34100 |
Day's range | 17.53 - 17.53 |
52-week range | 12.48 - 19.84 |
Volume | |
Avg. volume | 1,895 |
Market cap | 26.488B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 38.78 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.17 (0.93%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
COLORADO SPRINGS, Colo. & ALISO VIEJO, Calif., July 23, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms. The CLEVER study was a multicenter, prospective study evaluating the WEB 17 system in ruptured and unruptured aneurysms to understand the s
ALISO VIEJO, Calif., July 09, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of the SOFIA™ Aspiration System as first-line Technique (SOFAST): A prospective, multicenter study to assess the efficacy and safety of the 6 French SOFIA™ Flow Plus Aspiration Catheter for endovascular stroke thrombectomy, recently published in the Journal of NeuroInterventional Surgery (JNIS).
ALISO VIEJO, Calif., June 26, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide neck intracranial aneurysms. LVIS EVO has been available in Europe since 2019 and over 12,000 units have been sold. LVIS EVO is the first fully visible coil-assist-intracranial stent available in the US Market.